On January 5, 2022 Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, reported management’s participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022 (Press release, Ensysce Biosciences, JAN 5, 2022, View Sourcenews/press-releases/detail/52/ensysce-biosciences-announces-participation-in-the-h-c" target="_blank" title="View Sourcenews/press-releases/detail/52/ensysce-biosciences-announces-participation-in-the-h-c" rel="nofollow">View Source [SID1234598215]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An on-demand presentation from the H.C. Wainwright conference will be available through Ensysce’s Investor Relations website at View Source beginning January 10, 2022, at 7:00am ET.

The Company’s Chief Executive Officer Lynn Kirkpatrick, PhD and Chief Financial Officer Dave Humphrey will be available for one-on-one and small group meetings with investors. To schedule a meeting with Ensysce management, please contact your conference representative or you may also email your request to [email protected].